In women with a uterus, for the treatment of moderate to severe vasomotor symptoms associated with menopause, and prevention of postmenopausal ospeoporosis.
Administered in combination with irinotecan and 5‑fluorouracil (5‑FU) as part of chemotherapy for approved indications, including colorectal and gastric cancers.
maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid.